Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi
High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study inv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/9/1488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850258311660699648 |
|---|---|
| author | Benjamin Morgan Eleanor A. Lyons Amanda Handley Nada Bogdanovic-Sakran Daniel Pavlic Desiree Witte Jonathan Mandolo Ann Turner Khuzwayo C. Jere Frances Justice Darren Suryawijaya Ong Rhian Bonnici Karen Boniface Celeste M. Donato Ashley Mpakiza Anell Meyer Naor Bar-Zeev Miren Iturriza-Gomara Nigel A. Cunliffe Margaret Danchin Julie E. Bines |
| author_facet | Benjamin Morgan Eleanor A. Lyons Amanda Handley Nada Bogdanovic-Sakran Daniel Pavlic Desiree Witte Jonathan Mandolo Ann Turner Khuzwayo C. Jere Frances Justice Darren Suryawijaya Ong Rhian Bonnici Karen Boniface Celeste M. Donato Ashley Mpakiza Anell Meyer Naor Bar-Zeev Miren Iturriza-Gomara Nigel A. Cunliffe Margaret Danchin Julie E. Bines |
| author_sort | Benjamin Morgan |
| collection | DOAJ |
| description | High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (<i>p</i> < 0.005) and 3 (<i>p</i> < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease. |
| format | Article |
| id | doaj-art-5a77dd079b2640cba65a62a46ed3daa0 |
| institution | OA Journals |
| issn | 1999-4915 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-5a77dd079b2640cba65a62a46ed3daa02025-08-20T01:56:13ZengMDPI AGViruses1999-49152024-09-01169148810.3390/v16091488Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in MalawiBenjamin Morgan0Eleanor A. Lyons1Amanda Handley2Nada Bogdanovic-Sakran3Daniel Pavlic4Desiree Witte5Jonathan Mandolo6Ann Turner7Khuzwayo C. Jere8Frances Justice9Darren Suryawijaya Ong10Rhian Bonnici11Karen Boniface12Celeste M. Donato13Ashley Mpakiza14Anell Meyer15Naor Bar-Zeev16Miren Iturriza-Gomara17Nigel A. Cunliffe18Margaret Danchin19Julie E. Bines20Enteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaMalawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, MalawiMalawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, MalawiInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UKMalawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, MalawiEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaMalawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, MalawiEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UKInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UKInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UKEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaEnteric Diseases, Murdoch Children’s Research Institute, Parkville, VIC 3052, AustraliaHigh titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (<i>p</i> < 0.005) and 3 (<i>p</i> < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease.https://www.mdpi.com/1999-4915/16/9/1488rotavirus vaccinematernal antibodiesRV3-BB vaccine |
| spellingShingle | Benjamin Morgan Eleanor A. Lyons Amanda Handley Nada Bogdanovic-Sakran Daniel Pavlic Desiree Witte Jonathan Mandolo Ann Turner Khuzwayo C. Jere Frances Justice Darren Suryawijaya Ong Rhian Bonnici Karen Boniface Celeste M. Donato Ashley Mpakiza Anell Meyer Naor Bar-Zeev Miren Iturriza-Gomara Nigel A. Cunliffe Margaret Danchin Julie E. Bines Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi Viruses rotavirus vaccine maternal antibodies RV3-BB vaccine |
| title | Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi |
| title_full | Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi |
| title_fullStr | Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi |
| title_full_unstemmed | Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi |
| title_short | Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi |
| title_sort | rotavirus specific maternal serum antibodies and vaccine responses to rv3 bb rotavirus vaccine administered in a neonatal or infant schedule in malawi |
| topic | rotavirus vaccine maternal antibodies RV3-BB vaccine |
| url | https://www.mdpi.com/1999-4915/16/9/1488 |
| work_keys_str_mv | AT benjaminmorgan rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT eleanoralyons rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT amandahandley rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT nadabogdanovicsakran rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT danielpavlic rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT desireewitte rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT jonathanmandolo rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT annturner rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT khuzwayocjere rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT francesjustice rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT darrensuryawijayaong rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT rhianbonnici rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT karenboniface rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT celestemdonato rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT ashleympakiza rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT anellmeyer rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT naorbarzeev rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT mireniturrizagomara rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT nigelacunliffe rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT margaretdanchin rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi AT julieebines rotavirusspecificmaternalserumantibodiesandvaccineresponsestorv3bbrotavirusvaccineadministeredinaneonatalorinfantscheduleinmalawi |